Promising Results in EGFR-Mutated Lung Cancer with Iza-bren and Osimertinib Combination Therapy
A new study demonstrates that combining iza-bren with osimertinib yields a 100% response rate in patients with EGFR-mutated non-small cell lung cancer, offering hope for improved first-line treatment options.
A recent clinical study has revealed highly encouraging outcomes for patients with first-line EGFR-mutated non-small cell lung cancer (NSCLC) treated with a novel combination of iza-bren and osimertinib. Iza-bren, a groundbreaking bispecific antibody-drug conjugate (ADC) that targets EGFR and HER3 while delivering a topoisomerase I inhibitor payload, was paired with daily osimertinib, a third-generation EGFR tyrosine kinase inhibitor.
Presented at the 2025 World Conference on Lung Cancer, the study involved 154 patients across multiple dose levels. In particular, the group receiving 2.5 mg/kg of iza-bren achieved a 100% objective response rate (ORR), with a confirmed ORR of 95%, indicating that nearly all patients experienced tumor shrinkage. The median follow-up period was 12.8 months, with a 92.1% progression-free survival (PFS) rate at 12 months. Notably, the median duration of response and PFS had not yet been reached at the time of analysis.
The safety profile was manageable, with most treatment-related adverse events being hematologic, such as anemia (91.9%), neutropenia (91.1%), leukopenia (91.1%), and thrombocytopenia (75.6%). Non-hematologic side effects included nausea, stomatitis, decreased appetite, vomiting, diarrhea, and rash. Grade 3 or higher adverse events were controllable through supportive care and dose adjustments, with a discontinuation rate of 13%.
Dr. Fei Zhou, the lead investigator, expressed optimism about the findings, highlighting the potential for this combination to become a transformative first-line therapy for EGFR-mutant NSCLC. The promising activity and manageable safety profile suggest that future studies could solidify its place in lung cancer treatment options.
This groundbreaking research underscores ongoing advancements in targeted therapies for lung cancer, aiming to improve outcomes for patients with EGFR mutations.
For more details, visit the original report at Medical Xpress.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
'Rogue' Scaffolding Cells Could Unlock New Therapeutic Strategies for Multiple Diseases
New insights into fibroblast diversity reveal their central role in multiple diseases, opening possibilities for universal drug targets and innovative treatments across various tissues.
Research Uncovers Role of Spinal Ligaments in Scoliosis Development
New research highlights the crucial role of spinal ligament development in understanding scoliosis formation, using chick embryo models to uncover structural changes linked to spinal deformities.
Debunking the Risks of Mouth Taping During Sleep: What Science Says
Recent scientific reviews reveal that mouth taping during sleep offers limited benefits and poses significant safety risks, especially for individuals with nasal obstructions. Consult healthcare professionals for sleep issues.
Innovative Space-Based Study Unveils New Insights into Alzheimer's Protein Aggregation
Space experiments aboard the ISS have enabled the detailed structural analysis of Alzheimer's-related amyloid β fibrils, revealing new pathways in disease progression and showcasing the crucial role of microgravity in biomedical research.